{
    "clinical_study": {
        "@rank": "134444", 
        "acronym": "ICAT", 
        "arm_group": [
            {
                "arm_group_label": "CD25/71 allodepleted donor T-cells", 
                "arm_group_type": "Experimental", 
                "description": "CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant"
            }, 
            {
                "arm_group_label": "Control (normal HSCT)", 
                "arm_group_type": "No Intervention", 
                "description": "Patients randomised to the control arm with undergo stem cell transplantation according to site local practice."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate whether the administration of allodepleted donor T\n      cells to patients with acute myeloid leukaemia or acute lymphoblastic leukaemia after stem\n      cell transplant can improve the recovery of the patients immune system."
        }, 
        "brief_title": "Infusion of Depleted T Cells Following Transplant in Adults With Acute Leukaemia (ICAT)", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myeloid Leukaemia", 
            "Acute Lymphoblastic Leukaemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226516 years\n\n          -  Underlying acute myeloid or acute lymphoblastic leukaemia\n\n          -  Planned allogeneic peripheral blood stem cell transplantation from a 10/10 or 9/10\n             HLA matched unrelated donor, using an Alemtuzumab-based conditioning protocol\n\n          -  Written Informed consent\n\n        Exclusion Criteria:\n\n          -  Life expectancy < 6 weeks\n\n          -  Female patients who are pregnant and lactating\n\n          -  Patients who are serologically positive for Hepatitis B, C or HIV pre-SCT"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01827579", 
            "org_study_id": "UCL/11/0519", 
            "secondary_id": [
                "2013-000872-14", 
                "MR/K007491/1"
            ]
        }, 
        "intervention": {
            "arm_group_label": "CD25/71 allodepleted donor T-cells", 
            "description": "CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant", 
            "intervention_name": "CD25/71 allodepleted donor T-cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Transplant", 
            "CD25/71 allodepleted donor T cells", 
            "Infection", 
            "Acute Myeloid Leukaemia", 
            "Acute Lymphoblastic Leukaemia", 
            "Adult"
        ], 
        "lastchanged_date": "April 9, 2013", 
        "location": [
            {
                "contact": {
                    "email": "s.mackinnon@ucl.ac.uk", 
                    "last_name": "Steven Mackinnon"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Royal Free Hospital"
                }, 
                "investigator": {
                    "last_name": "Steven Mackinnon", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "karl.peggs@ucl.ac.uk", 
                    "last_name": "Karl Peggs"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "University College London Hospital"
                }, 
                "investigator": {
                    "last_name": "Karl Peggs", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Adoptive Immunotherapy With CD25/71 Allodepleted Donor T Cells to Improve Immunity After Unrelated Donor Stem Cell Transplant", 
        "overall_contact": {
            "email": "ctc.ICAT@ucl.ac.uk", 
            "last_name": "ICAT trial manager", 
            "phone": "020 7679 9327"
        }, 
        "overall_contact_backup": {
            "email": "l.clifton-hadley@ucl.ac.uk", 
            "last_name": "Laura Clifton-Hadley", 
            "phone": "0207 679 9138"
        }, 
        "overall_official": {
            "affiliation": "Great Ormond Street Hospital for Children NHS Foundation Trust", 
            "last_name": "Persis Amrolia", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Circulating CD3+ve T cell count at 4 months post-SCT", 
            "safety_issue": "No", 
            "time_frame": "4 months post transplant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01827579"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of grade II-IV acute and chronic GVHD", 
                "safety_issue": "Yes", 
                "time_frame": "1 year post transplant"
            }, 
            {
                "measure": "Time to recovery of normal T-cell (>700/uL) and CD4 (>300/uL) counts and normal TCR diversity as assessed by Vb spectratyping", 
                "safety_issue": "No", 
                "time_frame": "1 year post transplant"
            }, 
            {
                "measure": "In vitro anti-viral responses of circulating PBMC", 
                "safety_issue": "No", 
                "time_frame": "1 year post transplant"
            }, 
            {
                "measure": "Transplant related mortality at 1 year post-SCT", 
                "safety_issue": "No", 
                "time_frame": "1 year post transplant"
            }, 
            {
                "measure": "Disease-free survival  at 1 year post-SCT", 
                "safety_issue": "No", 
                "time_frame": "1 year post transplant"
            }
        ], 
        "source": "University College, London", 
        "sponsors": {
            "collaborator": {
                "agency": "Medical Research Council", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University College, London", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}